News
VIRX
0.1812
+0.39%
0.0007
Weekly Report: what happened at VIRX last week (1104-1108)?
Weekly Report · 17h ago
Viracta Therapeutics reports 42% reduction in force, strategic reprioritization
TipRanks · 5d ago
BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program
Reuters · 5d ago
Viracta Therapeutics Restructures to Focus on Nana-val Program
TipRanks · 5d ago
*Viracta Therapeutics: Expect to Recognize About $700,000 in Total Expenses for Severance and Related Benefits >VIRX
Dow Jones · 5d ago
*Viracta Therapeutics Announces Reprioritization of Resources
Dow Jones · 5d ago
*Viracta Therapeutics: Enhancing Focus on Nana-val Development Program in Certain Patients With T-Cell Lymphoma>VIRX
Dow Jones · 5d ago
*Viracta Therapeutics: Implementing 42% Reduction in Force and Resizing Bd of Directors to Six Seats From Ten >VIRX
Dow Jones · 5d ago
VIRACTA THERAPEUTICS INC: IMPLEMENTS 42% WORKFORCE REDUCTION
Reuters · 5d ago
Weekly Report: what happened at VIRX last week (1028-1101)?
Weekly Report · 11/04 09:27
Weekly Report: what happened at VIRX last week (1021-1025)?
Weekly Report · 10/28 09:25
Weekly Report: what happened at VIRX last week (1014-1018)?
Weekly Report · 10/21 09:25
Weekly Report: what happened at VIRX last week (1007-1011)?
Weekly Report · 10/14 09:29
Weekly Report: what happened at VIRX last week (0930-1004)?
Weekly Report · 10/07 09:27
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Seeking Alpha · 10/04 18:02
Weekly Report: what happened at VIRX last week (0923-0927)?
Weekly Report · 09/30 09:26
Weekly Report: what happened at VIRX last week (0916-0920)?
Weekly Report · 09/23 09:26
Weekly Report: what happened at VIRX last week (0909-0913)?
Weekly Report · 09/16 09:24
Weekly Report: what happened at VIRX last week (0902-0906)?
Weekly Report · 09/09 09:26
Weekly Report: what happened at VIRX last week (0826-0830)?
Weekly Report · 09/02 09:27
More
Webull provides a variety of real-time VIRX stock news. You can receive the latest news about Viracta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.